-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levoxiracetam in Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levoxiracetam in Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levoxiracetam in Cognitive Impairment Drug Details: L-oxiracetam is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Mild Cognitive Impairment Drug Details: Levetiracetam ER...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NE-3107 in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NE-3107 in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NE-3107 in Mild Cognitive Impairment Drug Details: NE-3107 (Triolex, HE3286) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NBI-1065846 in Cognitive Impairment Associated With Schizophrenia (CIAS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALTO-101 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALTO-101 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALTO-101 in Cognitive Impairment Associated With Schizophrenia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYN-5356 in Cognitive Impairment Associated With Schizophrenia (CIAS)...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment Associated With Schizophrenia (CIAS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...